S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.07%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.07%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.07%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.07%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
Log in
NASDAQ:PTCT

PTC Therapeutics Stock Forecast, Price & News

$64.15
+0.29 (+0.45 %)
(As of 12/3/2020 12:00 AM ET)
Add
Compare
Today's Range
$63.41
Now: $64.15
$64.67
50-Day Range
$51.22
MA: $57.59
$63.99
52-Week Range
$30.79
Now: $64.15
$64.67
Volume447,461 shs
Average Volume733,711 shs
Market Capitalization$4.38 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.08
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
PTC Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.07 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTCT
CUSIPN/A
Phone908-222-7000
Employees754

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$306.98 million
Book Value$9.64 per share

Profitability

Net Income$-251,580,000.00
Net Margins-138.67%

Miscellaneous

Market Cap$4.38 billion
Next Earnings Date3/1/2021 (Estimated)
OptionableOptionable
$64.15
+0.29 (+0.45 %)
(As of 12/3/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PTCT News and Ratings via Email

Sign-up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions

How has PTC Therapeutics' stock been impacted by COVID-19?

PTC Therapeutics' stock was trading at $47.08 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PTCT stock has increased by 36.3% and is now trading at $64.15.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of PTC Therapeutics?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 1 sell rating, 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for PTC Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than PTC Therapeutics?

Wall Street analysts have given PTC Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PTC Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is PTC Therapeutics' next earnings date?

PTC Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for PTC Therapeutics
.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its quarterly earnings data on Thursday, October, 29th. The biopharmaceutical company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.07. The biopharmaceutical company had revenue of $82.71 million for the quarter, compared to the consensus estimate of $112.21 million. PTC Therapeutics had a negative return on equity of 67.92% and a negative net margin of 138.67%. The business's revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.06) EPS.
View PTC Therapeutics' earnings history
.

What price target have analysts set for PTCT?

14 brokerages have issued 12 month target prices for PTC Therapeutics' stock. Their forecasts range from $45.00 to $86.00. On average, they anticipate PTC Therapeutics' stock price to reach $60.45 in the next year. This suggests that the stock has a possible downside of 5.8%.
View analysts' price targets for PTC Therapeutics
.

Who are some of PTC Therapeutics' key competitors?

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

Who are PTC Therapeutics' key executives?

PTC Therapeutics' management team includes the following people:
  • Dr. Stuart W. Peltz, Co-Founder, CEO & Exec. Director (Age 60, Pay $1.44M)
  • Dr. Allan Steven Jacobson, Independent Co-Founder, Chairman of Scientific Advisory Board & Director (Age 74, Pay $140k)
  • Ms. Emily Luisa Hill, CFO & Treasurer (Age 39, Pay $607.45k)
  • Ms. Christine Utter, Sr. VP, Chief Accounting Officer & Head of People Services (Age 42, Pay $595.54k)
  • Dr. Neil Almstead, Chief Technical Operations Officer (Age 53, Pay $742.2k)
  • Mr. Mark Elliott Boulding, Exec. VP & Chief Legal Officer (Age 59, Pay $733.42k)
  • Dr. Mark Jerome Pykett, Chief Scientific Officer (Age 56)
  • Alex Kane, Investor Relations Officer
  • Ms. Jane Baj, VP of Corp. Communications
  • Ms. Hege Sollie-Zetlmayer, Sr. VP of HR

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (8.42%), State Street Corp (3.35%), Point72 Asset Management L.P. (1.61%), Candriam Luxembourg S.C.A. (1.11%), Charles Schwab Investment Management Inc. (0.65%) and UBS Asset Management Americas Inc. (0.63%). Company insiders that own PTC Therapeutics stock include Allan Steven Jacobson, Christine Marie Utter, Emily Luisa Hill, Eric Pauwels, Marcio Souza, Mark Elliott Boulding, Michael Schmertzler, Neil Gregory Almstead and Stuart Walter Peltz.
View institutional ownership trends for PTC Therapeutics
.

Which major investors are selling PTC Therapeutics stock?

PTCT stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Wells Fargo & Company MN, Sofinnova Investments Inc., UBS Asset Management Americas Inc., State Street Corp, AQR Capital Management LLC, Sei Investments Co., and Candriam Luxembourg S.C.A.. Company insiders that have sold PTC Therapeutics company stock in the last year include Allan Steven Jacobson, Christine Marie Utter, Emily Luisa Hill, Eric Pauwels, Marcio Souza, Mark Elliott Boulding, Neil Gregory Almstead, and Stuart Walter Peltz.
View insider buying and selling activity for PTC Therapeutics
.

Which major investors are buying PTC Therapeutics stock?

PTCT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., BlackRock Inc., DekaBank Deutsche Girozentrale, Polar Capital LLP, Polar Capital LLP, Tygh Capital Management Inc., Handelsbanken Fonder AB, and Cubist Systematic Strategies LLC.
View insider buying and selling activity for PTC Therapeutics
.

How do I buy shares of PTC Therapeutics?

Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $64.15.

How big of a company is PTC Therapeutics?

PTC Therapeutics has a market capitalization of $4.38 billion and generates $306.98 million in revenue each year. The biopharmaceutical company earns $-251,580,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis. PTC Therapeutics employs 754 workers across the globe.

What is PTC Therapeutics' official website?

The official website for PTC Therapeutics is www.ptcbio.com.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.